Form 8-K - Current report:
SEC Accession No. 0001193125-23-291662
Filing Date
2023-12-08
Accepted
2023-12-08 16:02:52
Documents
16
Period of Report
2023-12-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d613658d8k.htm   iXBRL 8-K 24981
2 EX-99.1 d613658dex991.htm EX-99.1 10370
3 EX-99.2 d613658dex992.htm EX-99.2 11962
4 EX-99.3 d613658dex993.htm EX-99.3 10557
8 GRAPHIC g613658g1209004537996.jpg GRAPHIC 4091
  Complete submission text file 0001193125-23-291662.txt   196882

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eypt-20231205.xsd EX-101.SCH 2860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20231205_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20231205_pre.xml EX-101.PRE 10819
10 EXTRACTED XBRL INSTANCE DOCUMENT d613658d8k_htm.xml XML 3226
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 231475342
SIC: 3826 Laboratory Analytical Instruments